Heparin in malignant glioma: review of preclinical studies and clinical results
about
Juglone reduces growth and migration of U251 glioblastoma cells and disrupts angiogenesis.Extracellular Vesicles in Brain Tumor Progression.Dabigatran antagonizes growth, cell-cycle progression, migration, and endothelial tube formation induced by thrombin in breast and glioblastoma cell lines.Localized targeted antiangiogenic drug delivery for glioblastoma.
P2860
Heparin in malignant glioma: review of preclinical studies and clinical results
description
2015 nî lūn-bûn
@nan
2015 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Heparin in malignant glioma: review of preclinical studies and clinical results
@ast
Heparin in malignant glioma: review of preclinical studies and clinical results
@en
Heparin in malignant glioma: review of preclinical studies and clinical results
@nl
type
label
Heparin in malignant glioma: review of preclinical studies and clinical results
@ast
Heparin in malignant glioma: review of preclinical studies and clinical results
@en
Heparin in malignant glioma: review of preclinical studies and clinical results
@nl
prefLabel
Heparin in malignant glioma: review of preclinical studies and clinical results
@ast
Heparin in malignant glioma: review of preclinical studies and clinical results
@en
Heparin in malignant glioma: review of preclinical studies and clinical results
@nl
P2093
P2860
P921
P3181
P1476
Heparin in malignant glioma: review of preclinical studies and clinical results
@en
P2093
Marike L. D. Broekman
Rosalie Schnoor
Sybren L. N. Maas
P2860
P2888
P3181
P356
10.1007/S11060-015-1826-X
P407
P5008
P577
2015-09-01T00:00:00Z
P5875
P6179
1028039377